RT Journal Article
SR Electronic
T1 Safety, tolerability and clinical effects of BC007 (Rovunaptabin) on fatigue and quality of life in patients with post-COVID syndrome (reCOVer): a prospective, exploratory, randomised, placebo-controlled, double-blind, crossover phase IIa clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.13.24318856
DO 10.1101/2024.12.13.24318856
A1 Hohberger, Bettina
A1 Ganslmayer, Marion
A1 Harrer, Thomas
A1 Kruse, Friedrich
A1 Maas, Stefanie
A1 Borst, Tobias
A1 Heimke-Brinck, Ralph
A1 Stog, Andreas
A1 Knauer, Thomas
A1 Rühl, Eva
A1 Zeisberg, Victoria
A1 Skornia, Adam
A1 Bartsch, Alexander
A1 Ströbel, Armin
A1 Wytopil, Monika
A1 Merkel, Carolin
A1 Hofmann, Sophia
A1 Schmidt, Katja G.
A1 Lakatos, Petra
A1 Schottenhamml, Julia
A1 Herrmann, Martin
A1 Mardin, Christian
A1 Rech, Jürgen
YR 2024
UL http://medrxiv.org/content/early/2024/12/14/2024.12.13.24318856.abstract
AB Background As recent data suggest an involvement of GPCR-fAAb in PCS pathogenesis, neutralisation of such GPCR-fAAbs by BC007 could improve PCS symptoms. The aim of the reCOVer trial was to investigate safety, tolerability and clinical effects of BC007 on fatigue, its severity and quality of life in PCS patients.Methods reCOVer is a prospective, exploratory, randomised, placebo-controlled, double-blind, crossover phase IIa clinical trial with 1350 mg BC007 at the University of Erlangen-Nürnberg, Germany. Eligible participants were 18-80 years with GPCR-fAAb, whose PCS symptoms persisted ≥3 months after PCR-confirmed COVID-19, with fatigue as the major symptom (Bell score ≤60) and at least three of eight defined PCS symptoms. Participants were randomly assigned (1:1) according to a crossover design to either receive BC007 (sequence A) or placebo (sequence B) at day 0 and day 48 with a follow-up of 28 days, respectively. A crossover design was chosen to increase patient adherence. Occurrence of treatment-emergent adverse events (TEAEs) in comparison between sequence A and B from d0 to d28 and d0 to d70 were the primary and co-primary endpoint, respectively.Findings Between 31.10.2023 and 12.06.2024, 30 PCS patients were randomised and analysed. The trial has been concluded. Summarising all AE rates, no statistically significant differences between sequence A und sequence B were observed within day 28 and day 70. One report of a serious adverse event, not related to treatment, was recorded. As a secondary endpoint, BC007 showed a significant improvement on self-reported fatigue and its severity, as well as quality of life.Interpretation As BC007 was well tolerated and showed a significant improvement of fatigue and quality of life, it might offer a therapeutic option for an autoimmune subgroup of PCS patients.Trial registration EudraCT, number 2022-001781-35.Funding German Federal Ministry of Education and Research, German Research Foundation.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEudraCT No.: 2022-001781-35Funding StatementThis study was funded by the German Federal Ministry of Education and Research, BMBF, grant number 01EP2108A (reCOVer) and 01EO2105 (iIMMUNE_ACS) as well as the German Research Foundation (DFG), grant number 401821119/GRK2504Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the Friedrich-Alexander-Universitaet Erlangen-Nuernberg, Erlangen, Germany gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.